Dosing Strategies and Quantitative Clinical Pharmacology for Bispecific T-Cell Engagers Development in OncologyCLINICAL PHARMACOLOGY & THERAPEUTICSIF5.52024-07-044OAAI
Subcutaneous Biologics: Clinical Pharmacology and Drug DevelopmentCLINICAL PHARMACOLOGY & THERAPEUTICSIF5.52024-02-160OAAI
Evaluating the performance of the USPSTF lung cancer screening guidelines in an Asian population of lung cancer patientsANNALS OF ONCOLOGYIF65.42023-11-010PRE
A phase Ia study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of a modular CLDN18.2-targeting PG CAR-T therapy (IBI345) in patients with CLDN18.2+solid tumorsANNALS OF ONCOLOGYIF65.42023-10-012PRE
Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: phase 1 trial resultsNATURE MEDICINEIF502023-04-0346OAAI
A literature review of liver function test elevations in rifampin drug-drug interaction studiesCTS-CLINICAL AND TRANSLATIONAL SCIENCEIF2.82022-05-096OAAI
Response to Lorlatinib Exposed: A Far from Optimal DoseCLINICAL PHARMACOLOGY & THERAPEUTICSIF5.52022-03-311PRE
Diagnosis, Evaluation, and Treatment of AdenomyosisJAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATIONIF552021-07-1347PRE
Lorlatinib Exposure-Response Analyses for Safety and Efficacy in a Phase I/II Trial to Support Benefit-Risk Assessment in Non-Small Cell Lung CancerCLINICAL PHARMACOLOGY & THERAPEUTICSIF5.52021-06-2621OAAI
Liver Toxicity Observed With Lorlatinib When Combined With Strong CYP3A Inducers: Evaluation of Cynomolgus Monkey as a Nonclinical Model for Assessing the Mechanism of Combinational ToxicityTOXICOLOGICAL SCIENCESIF4.12021-05-216PREAI
Population pharmacokinetic model with time-varying clearance for lorlatinib using pooled data from patients with non-small cell lung cancer and healthy participantsCPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGYIF32021-02-0114OAAI
The Effect of Rifampin on the Pharmacokinetics and Safety of Lorlatinib: Results of a Phase One, Open-Label, Crossover Study in Healthy Participants (vol 37, pg 745, 2020)ADVANCES IN THERAPYIF42020-09-100PREAI
Characterization of the Relationship of Inotuzumab Ozogamicin Exposure With Efficacy and Safety End Points in Adults With Relapsed or Refractory Acute Lymphoblastic LeukemiaCTS-CLINICAL AND TRANSLATIONAL SCIENCEIF2.82020-08-186OAAI
The Effect of Rifampin on the Pharmacokinetics and Safety of Lorlatinib: Results of a Phase One, Open-Label, Crossover Study in Healthy ParticipantsADVANCES IN THERAPYIF42019-12-2028PREAI
The effect of itraconazole on the pharmacokinetics of lorlatinib: results of a phase I, open-label, crossover study in healthy participantsINVESTIGATIONAL NEW DRUGSIF2.72019-11-1418PREAI
Endoscopic evaluation and management of colonic postpolypectomy hemorrhageGASTROINTESTINAL ENDOSCOPYIF7.52008-04-011PREAI
Characterization of a tissue factor/factor VIIa-dependent model of thrombosis in hypercholesterolemic rabbitsJOURNAL OF THROMBOSIS AND HAEMOSTASISIF52004-01-0121PREAI
Low dose ethanol potentiates indomethacin induced inhibition of wound re-epithelialization in duodenal monolayersLIFE SCIENCESIF5.12002-05-013PREAI
个人简介
教育背景
工作经历
荣誉奖项
未登录.png){kind=icon}
未登录个人简介教育背景工作经历荣誉奖项
研究方向